Success Stories

white pills
Creating a fast track to new treatment is the pathway the Institute is developing within the motivational need to help people and improve patient care.

Seven new drugs since 2009

In December 2008, IAMI was created with a mission to improve patient care by accelerating new drug therapies and medical devices to patients. IAMI took this opportunity to focus on reformulating and repurposing approved drugs. This created rich collaboration across the University of Kansas campus, the Kansas City community and the nation. Creating a fast track to new treatment is the pathway the Institute is developing within the motivational need to help people and improve patient care.

Children: New drug therapies

  • Acute lymphoblastic leukemia (ALL) is a type of leukemia most common in children. The Institute leaders and clinicians from Children's Mercy Hospital in Kansas City have collaborated to open a pediatric clinical trial for ALL remission patients. Through this partnership, the Institute leaders reformulated a new drug therapy for children that clinicians at Children's Mercy Hospital were seeking to treat their young patients.
  • The Institute also reformulated Hydroxyurea, a chemotherapy agent used for many years to treat people with certain cancers for use in treating children with sickle-cell disease, most often presented in children. The Institute in collaboration with the Institute for Pediatric Innovation has reformulated Enalapril, an ACE inhibitor, into a drug therapy for children.

"What motivates us (the Institute) is not to develop the next big blockbuster drug but to apply our expertise to these problems and help children." Scott Weir, Institute Director

Adult: New drug therapies

  • Acute myeloid leukemia (AML), present in adults, is the most common acute leukemia.  The Institute provided services to repurpose an antifungal; drug, Ciclopirox, as a new option to cancer patients in clinical trials.  Leukemia & Lymphoma Society (LLS) and the Ontario Cancer Institute were partners in this effort and continue to collaborate with IAMI.  Additionally, Tigecycline, an antibiotic, has also been repurposed for AML patients and is in clinical trials. LLS and the Ontario Cancer Institute are partners for Tigecycline as well.
  • The Learning Collaborative (TLC) project, is a partnership with the National Institutes of Health and the Leukemia & Lymphoma Society and is serving as a national model for academic, government and non-profit collaboration.  Thus far, the partnership has advanced auranofin, an off-patent drug approved fro the treatment of rheumatoid arthritis, to clinical evaluation for the treatment of chronic lymphocytic leukemia (CLL).  CLL is the most common type of leukemia.
  • And lastly, Melphalan was licensed to a Kansas startup, Cydex.  Cydex applied platform drug delivery technology that was licensed from KU to address formulation shortcomings of the marketed formulation. Melphalan is designed to deliver a new treatment for multiple myeloma adult patients.

Last modified: Mar 29, 2013